Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications

被引：0
作者：
Satomi Onoue
Shingen Misaka
Shizuo Yamada
机构：
[1] University of Shizuoka,Department of Pharmacokinetics and Pharmacodynamics and Global Center of Excellence (COE) Program, School of Pharmaceutical Sciences
来源：
Naunyn-Schmiedeberg's Archives of Pharmacology | 2008年 / 377卷
关键词：
VIP; PAC1; VPAC1; VPAC2; Structure–activity relationship; DDS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Vasoactive intestinal peptide (VIP) has been identified as one of major peptide transmitters in the central and peripheral nervous systems, being involved in a wide range of biological functions. The general physiologic effects of VIP include vasodilation, anti-inflammatory actions, cell proliferation, hormonal secretion, regulation of gastric motility, and smooth muscle relaxation; therefore, VIP has emerged as a promising drug candidate for the treatment of several diseases. A number of clinical applications of VIP or its derivatives have been developed; however, VIP-based drugs are not yet in clinical use, possibly because of mainly two serious problems: (1) poor metabolic stability and (2) poor penetration to the desired site of action. To overcome these shortcomings, the development of efficacious VIP analogues and several drug delivery systems has been attempted on the basis of numerous structure–activity relationships (SAR) studies and pharmacological experiments. Combination of the use of potent VIP analogues and an appropriate drug delivery system might be advantageous for the VIP-based therapy. We review in this paper SAR studies of VIP for the identification of potent therapeutic agents, describe the development of selective and/or metabolically stable VIP receptor agonists/antagonists, and discuss the potential application for clinical treatment using drug delivery systems.
引用
收藏
页码：579 / 590
页数：11
相关论文
共 547 条
  • [1] Abad C(2003)Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease Gastroenterology 124 961-971
  • [2] Martinez C(2006)Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP Curr Top Med Chem 6 151-163
  • [3] Juarranz MG(2004)Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP(1–38) in pegylated phospholipid micelles Peptides 25 1253-1258
  • [4] Arranz A(2000)Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development J Comp Neurol 425 495-509
  • [5] Leceta J(1988)Dysfunction of the gastrointestinal peptide in peristalsis and sphincter function Ann N Y Acad Sci 527 545-567
  • [6] Delgado M(1993)Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery Proc Natl Acad Sci U S A 90 2618-2622
  • [7] Gomariz RP(1996)NMR spectroscopic evidence that helodermin, unlike other members of the secretin/VIP family of peptides, is substantially structured in water Biochemistry 35 5955-5962
  • [8] Abad C(1986)Conformation of peptides of the secretin–VIP–glucagon family in solution Peptides 7 43-48
  • [9] Gomariz RP(1974)A preferred conformation in the vasoactive intestinal peptide (VIP). Molecular architecture of gastrointestinal hormones Bioorg Chem 3 133-140
  • [10] Waschek JA(1992)Degradation of vasoactive intestinal peptide in bronchoalveolar lavage fluid Biomed Res 13 25-30
12345678910